Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: A randomized, placebo-controlled, crossover trial

BMC Pulmonary Medicine

Volumn 14, Issue 1, 2014, Pages

  Beeh, Kai M ^a   Watz, Henrik ^b   Puente Maestu, Luis ^c   de Teresa, Luis ^d   Jarreta, Diana ^e   Caracta, Cynthia ^f   Gil, Esther Garcia ^e   Magnussen, Helgo ^b  

^a Institut fur Atemwegsforschung INSAF   (Germany)

^b Member of the German Center for Lung Research   (Germany)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d Hospital de San Vicente   (Spain)

^e ASTRAZENECA   (United Kingdom)

^f Forest Laboratories   (United States)

Author keywords

Aclidinium; COPD; Exercise endurance; Long acting muscarinic antagonists; Physical activity

Indexed keywords

ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; OXYGEN; PLACEBO; PREDNISONE; SALBUTAMOL; THEOPHYLLINE;

ACCELEROMETER; ACCELEROMETRY; ADULT; ARTICLE; BICYCLE ERGOMETRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CONTROL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG WITHDRAWAL; DRY POWDER INHALER; DYSPNEA; ENDURANCE; EXERCISE INTENSITY; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PHASE 3 CLINICAL TRIAL; PHYSICAL ACTIVITY; PHYSICAL CAPACITY; PLETHYSMOGRAPHY; PREDICTION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SPIROMETRY; SUSTAINED RELEASE FORMULATION; TASTE DISORDER; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84928794287     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-14-209     Document Type: Article

References (30)

1. Arne M, Lundin F, Boman G, Janson C, Janson S, Emtner M: Factors associated with good self-rated health and quality of life in subjects with self-reported COPD. Int J Chron Obstruct Pulmon Dis 2011, 6:511-519.
2. Eisner MD, Iribarren C, Yelin EH, Sidney S, Katz PP, Ackerson L, Lathon P, Tolstykh I, Omachi T, Byl N, Blanc PD: Pulmonary function and the risk of functional limitation in chronic obstructive pulmonary disease. Am J Epidemiol 2008, 167:1090-1101.
3. Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M, Pérez-Izquierdo J, Aizpiri S, Aguirre U, Capelastegui A: Impact of changes in physical activity on health-related quality of life among patients with COPD. Eur Respir J 2010, 36:292-300.
4. Jones PW: Activity limitation and quality of life in COPD. COPD 2007, 4:273-278.
5. O'Donnell DE, Laveneziana P: Dyspnea and activity limitation in COPD: mechanical factors. COPD 2007, 4:225-236.
6. Thomas M, Decramer M, O'Donnell DE: No room to breathe: the importance of lung hyperinflation in COPD. Prim Care Respir J 2013, 22:101-111.
7. Cooper CB: The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 2006, 119:21-31.
8. Puente-Maestu L, de García PJ, Martínez-Abad Y, Ruíz de Oña JM, Llorente D, Cubillo JM: Dyspnea, ventilatory pattern, and changes in dynamic hyperinflation related to the intensity of constant work rate exercise in COPD. Chest 2005, 128:651-656.
9. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
10. O'Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H: Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004, 23:832-840.
11. O'Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Swales J, Lawrence D, Kramer B: Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011, 105:1030-1036.
12. Casaburi R: Factors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventions. COPD 2005, 2:131-136.
13. Beeh KM, Singh D, Di Scala L, Drollmann A: Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012, 7:503-513.
14. Food and Drug Administration: Tudorza® Pressair® (aclidinium bromide). [http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails]
15. European Medicines Agency: Eklira® Genuair® (aclidinium bromide). [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002211/human_med_001571.jsp&mid=WC0b01ac058001d124]
16. Maltais F, Celli B, Casaburi R, Porszasz J, Jarreta D, Seoane B, Caracta C: Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 2011, 105:580-587.
17. ATS/ACCP: Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003, 167:211-277.
18. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, MacIntyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G: Standardisation of the measurement of lung volumes. Eur Respir J 2005, 26:511-522.
19. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
20. Watz H, Waschki B, Meyer T, Magnussen H: Physical activity in patients with COPD. Eur Respir J 2009, 33:262-272.
21. Guenette JA, Webb KA, O'Donnell DE: Does dynamic hyperinflation contribute to dyspnoea during exercise in patients with COPD? Eur Respir J 2012, 40:322-329.
22. Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D'Andrea P, Banerji D: Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med 2014, 108:584-592.
23. Puente-Maestu L, Villar F, de Miguel J, Stringer WW, Sanz P, Sanz ML, García de Pedro J, Martínez-Abad Y: Clinical relevance of constant power exercise duration changes in COPD. Eur Respir J 2009, 34:340-345.
24. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Mölken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-468.
25. Wen CP, Wai JP, Tsai MK, Yang YC, Cheng TY, Lee MC, Chan HT, Tsao CK, Tsai SP, Wu X: Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet 2011, 378:1244-1253.
26. Waschki B, Kirsten A, Holz O, Muller KC, Meyer T, Watz H, Magnussen H: Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011, 140:331-342.
27. Garcia-Rio F, Rojo B, Casitas R, Lores V, Madero R, Romero D, Galera R, Villasante C: Prognostic value of the objective measurement of daily physical activity in patients with COPD. Chest 2012, 142:338-346.
28. Beier J, Kirsten AM, Mróz R, Segarra R, Chuecos F, Caracta C, Garcia Gil E: Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD 2013, 10:511-522.
29. Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, Segarra R, Caracta C, Garcia Gil E: Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012, 40:830-836.
30. Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF, ACCORD I study investigators: Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012, 9:90-101.